Transforming Care with GROUND-BREAKING Molecular Imaging Technology
We are passionate about developing new imaging solutions to enable the delivery of personalised medicine to more patients – ensuring each individual receives the right treatment at the right time.
Images courtesy of Prof C Becker, University of Oxford, Dr T Garrood, Guy’s Hospital and Dr G Dixon, University of Exeter
Serac Healthcare is developing innovative imaging solutions for unmet medical needs.
Serac Healthcare is focused on bringing to market a molecular imaging agent, maraciclatide, in endometriosis, interstitial lung disease and inflammatory arthritis. Serac Healthcare is exploring the potential for this novel imaging marker to enable earlier and more effective treatment decisions to improve the quality of life and outcomes for patients and to reduce healthcare costs.
Bringing personalised medicine to inflammatory arthritis
Therapies that can slow or even halt disease progression are available, but their effective use is dependent upon an accurate assessment of disease activity (inflammation) in the joints. However, it remains a challenge to identify which treatment is best for each patient.
99mTc-maraciclatide planar imaging has the potential to image the whole body, highlighting total inflammatory load in the joints in a 20-minute scan, producing images that are easy to interpret even to the untrained observer.
Developing a non-invasive test for endometriosis
The growth of endometrial tissue is dependent upon the development of new blood vessels (angiogenesis), which studies have shown can be imaged with 99mTc-maraciclatide.
Endometriosis is extremely hard to diagnose as there are so many possible causes of the symptoms associated with endometriosis. A definitive diagnosis for all types of endometriosis requires invasive laparoscopic surgery.
Distinguishing Inflammation And Fibrosis In Interstitial Lung Disease (ILD)
ILD symptoms are non-specific and often present late in disease progression, making early detection extremely difficult. While symptom management therapies are available, inappropriate administration can prove more detrimental than beneficial.
A non-invasive imaging solution capable of distinguishing inflammation and fibrosis predominant ILD has the potential to meaningfully advance diagnosis, change the treatment paradigm and improve patient outcomes.
Pain regarded as normal or expected part of menstruation
Early symptoms can be vague and mistaken for other conditions
Patients may not be comfortable discussing menstrual issues with physicians
Physicians and patients might lack awareness of endometriosis
9 year average to diagnosis
which often requires surgery
No imaging solution exists for the most common subtype of endometriosis: superficial peritoneal disease
Endometriosis - a diagnostic challenge
Endometriosis is a common inflammatory disease that affects one in 10 women and female-born individuals during their childbearing years, about 190 million women worldwide.
It occurs when endometrial tissue, which lines the uterus (the endometrium), grows in any other part of the body.
Endometriosis is frequently painful and is associated with infertility. It typically results in multiple physician and hospital visits, multiple scans and often laparoscopic (keyhole) surgery is the only way to reach a definitive diagnosis.
As a result, there is an average delay of approximately 9 years to secure a diagnosis. A significant factor in this delay is the lack of non-invasive tests capable of detecting all types of endometriosis.
Inflammatory arthritis - a disease management challenge
Inflammatory arthritis encompasses several chronic, progressive, painful, incurable conditions in which the body’s own immune system attacks the joints. If untreated they can result in irreversible joint damage and permanent disability. Multiple therapies are available that can slow or even halt disease progression, but difficulty in determining when joints are inflamed means that patients are often over or under treated.
Physical examination: subjective and does not always correlate to underlying disease
Blood tests: no definitive marker
X-ray: images irreversible damage already done to the joints
Ultrasound: operator-dependent, time-consuming and suitable only for a small number of joints
MRI: expensive and not always readily accessible
Interstitial Lung Disease – A Diagnostic Differentiation Challenge
Interstitial lung diseases are a heterogenous group of over 200 irreversible conditions with varying degrees of inflammation that, without treatment, lead to scarring (fibrosis) of the lining of the lungs. ILD symptoms are non-specific and often present late in disease progression, making early detection extremely difficult. While symptom management therapies are available, including powerful anti-inflammatory agents, physicians currently have no way of distinguishing between inflammation and fibrosis in order to determine the most appropriate treatment for each patient. Prescribing the wrong treatment can make the condition worse.
ILD is characterized by progressive inflammation, fibrosis, and reduced quality of life
Average life expectancy in patients with severe ILD is 3-5 years
Anti-inflammatory therapies can slow progression when inflammation predominates; yet they can be detrimental once fibrosis is established
Determining the most appropriate treatment is extremely challenging due to current diagnostic limitations
ILD progression is unpredictable, making prognostication challenging and creating barriers to effective drug development
99mTc-Maraciclatide
Our groundbreaking molecular imaging agent being investigated for endometriosis, interstitial lung disease and inflammatory arthritis.
Empowering Clinicians
See how our technology will empower physicians.
About us
Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing, and commercialising innovative molecular imaging technologies.
Using these targeted technologies to underpin personalised medicine in the fields of endometriosis, inflammatory arthritis and interstitial lung disease, Serac Healthcare is focused on bringing to market effective tools to accelerate diagnosis and to enable earlier and more effective treatment decisions.
Investment opportunities
Serac Healthcare is developing maraciclatide to address major unmet medical and societal needs.
Serac Healthcare is a privately owned, clinical-stage radiopharmaceutical company. We are always ready to talk to investors who match our ambitions and can help us excel. If you would like to discuss investment opportunities, please do get in touch.
Latest News
- 01/06/2026
⁹⁹ᵐTc-Maraciclatide Demonstrates Potential to Differentiate Inflammation from Fibrosis in Interstitial Lung Disease
Phase 2 99mTc-maraciclatide data presented at SNMMI 2026 Annual Meeting show distinct αvβ3 integrin uptake in patients with ILD
London, UK, 1 June 2026. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, 99mTc-maraciclatide, has presented Phase 2 data showing that SPECT-CT imaging with 99mTc-maraciclatide has the potential to identify and differentiate active inflammation from fibrosis in patients with interstitial lung disease (ILD). The findings were presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Los Angeles, USA, taking place from 30 May to 2 June and have been highlighted in an SNMMI press release: “New SPECT Imaging Approach Distinguishes Inflammation from Fibrosis to Optimize Treatment for Lung Disease.”
These encouraging Phase 2 results demonstrate that imaging with 99mTc-maraciclatide has the potential to meet a number of unmet clinical needs:
- Differentiating inflammation from fibrosis to inform treatment selection
- Identifying co-existent inflammation in patients with established fibrotic disease to inform treatment approach
- Providing a screening tool for ILD in rheumatoid arthritis (RA) patients based on established risk factors; and
- Enabling early identification and monitoring of RA-associated ILD for disease progression and therapy response.
ILD encompasses a heterogeneous group of lung conditions characterised by varying degrees of inflammation and fibrosis. Accurately distinguishing between the two is critical to clinical management, yet there is currently no reliable, non-invasive method to identify active inflammation in the lungs.
99mTc-maraciclatide is a gamma-emitting radiotracer that binds to αvβ3 integrin, which is upregulated during angiogenesis (new blood vessel formation), a cardinal feature of inflammatory diseases. The investigational agent has previously demonstrated diagnostic utility in other inflammatory conditions, including endometriosis and rheumatoid arthritis.
The 15 patient substudy is part of the “PRospective Evaluation of Interstitial Lung Disease progression with quantitative CT (PREDICT-ILD)” Phase 2 clinical trial which is being run by a team from the University of Exeter, a world-leading research centre for lung disease. Investigators evaluated 99mTc-maraciclatide in patients with two distinct forms of ILD: idiopathic pulmonary fibrosis (IPF) and fibrotic hypersensitivity pneumonitis (fHP), alongside healthy controls (n=5 per group). Fused images were independently evaluated to assess radiological patterns, distribution, and standardised uptake values (SUV). A target-to-background ratio (TBR) was derived from maximum and minimum lung SUV.
Both IPF and fHP patient cohorts showed distinct uptake in the lungs compared with healthy controls. Mean lung SUV was significantly higher in the fHP cohort versus healthy controls, and numerically higher for IPF; mean TBR was also numerically higher in both patient groups. The more pronounced uptake observed in fHP, a condition in which active inflammation typically co-exists with fibrosis, compared with IPF, in which inflammation is not a defining feature, is biologically consistent with the mechanism of action of maraciclatide.
Commenting on the findings, Dr Druin Burch, Scientific Director of Serac Healthcare, said:
“ILD is a pernicious and painful condition affecting millions of patients worldwide. Inflammatory and fibrotic disease have distinct pathophysiological mechanisms, prognostic implications, and therapeutic requirements, yet there is no non-invasive way of making this distinction. If these results are replicated in a larger study, maraciclatide has the potential to have an immediate impact on clinical outcomes.”
David Hail, Chief Executive of Serac Healthcare added:
“The ability to visualise inflammation non-invasively, and to distinguish it from fibrosis, addresses an urgent unmet need in ILD. For clinicians managing these patients, the ability to visualise and identify disease activity has the potential to inform and improve clinical decisions and also to enable the development of new therapies.”
The ILD data add to a growing body of clinical evidence for 99mTc-maraciclatide across multiple inflammatory conditions. Maraciclatide holds US FDA Fast Track Designation for both endometriosis and ILD indications.
Analysis of the Phase 2 study is ongoing; Phase 3 studies in ILD are being planned.
Maraciclatide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.
Images are available on request.
The abstract 261910. “Imaging Lung Inflammation in Interstitial Lung Disease (ILD) with 99mTc-Maraciclatide – a Therapy Selection Tool?” is available on the SNMMI website and on the Serac Healthcare website here.
Details on the PREDICT-ILD study can be found at www.clinicaltrials.gov : NCT05609201
For more information, please contact:
Serac Healthcare Ltd
www.serachealthcare.com
David Hail, Chief Executive
+44 (0)20 8948 0000
info@seraclifesciences.com
Francetta Carr, Communications
+44 (0)7711 010820
francettacarr@seraclifesciences.com
Notes to Editors
Serac Healthcare Ltd
Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Using these targeted technologies to underpin personalised medicine in the fields of endometriosis, inflammatory arthritis and interstitial lung disease, Serac Healthcare is focused on bringing to market effective tools to accelerate diagnosis, and to deliver earlier and more effective treatment decisions. Serac Healthcare Ltd is a wholly owned subsidiary of Serac Life Sciences Limited. www.serachealthcare.com
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit snmmi.org.
- 30/05/2026
First US Presentation of DETECT Data Demonstrates Semi-Quantitative Assessment of Endometriosis Lesions Using ⁹⁹ᵐTc-Maraciclatide
Poster presented at SNMMI 2026 shows standardised uptake metrics align with lesion type and expected levels of angiogenesis, including for superficial peritoneal disease
London, UK, 30 May 2026. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, 99mTc-maraciclatide, announces the presentation of a poster at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting reporting semi-quantitative imaging data from the DETECT Phase 2 study of 99mTc-maraciclatide in endometriosis.
The poster is available in the Science Pavilion throughout the meeting, which runs from 30 May to 2 June 2026 in Los Angeles and the author will be giving a brief introduction on its contents at a Meet the Author session from 1-1.45pm on Sunday 31st May in the Science Pavilion, South Hall GHJK (Convention Center); MTA01.
The DETECT study has previously demonstrated that SPECT-CT imaging with 99mTc-maraciclatide can visually detect endometriotic lesions, including superficial peritoneal disease which is not reliably visualised with existing imaging modalities. 99mTc-maraciclatide binds with high affinity to αvβ3 integrin, a receptor upregulated during angiogenesis, enabling the non-invasive localisation of active endometriotic lesions.
The poster presents new semi-quantitative analysis of imaging data from the DETECT study with known or suspected endometriosis who underwent SPECT-CT scanning with 99mTc-maraciclatide prior to laparoscopy. Standardised metrics were applied to regions of abnormal tracer uptake to derive measures of lesion size and specific uptake ratio, and compared with surgical findings. These metrics show alignment with the different sizes and expected levels of angiogenesis associated with superficial disease, deep disease, and endometriomas. The use of specific uptake ratios could provide a framework for an objective measurement of response to treatment.
Presenting the findings, Dr Druin Burch, Chief Scientific Officer of Serac Healthcare, said: “The development of robust semi-quantitative tools is an important step towards the clinical translation of maraciclatide. Standardised measures of uptake and lesion characteristics not only support reproducible image interpretation but also open the door to potential applications in monitoring disease activity and evaluating novel therapies.”
David Hail, Serac Healthcare Chief Executive, added,
“Advancements in imaging for endometriosis have been identified as a global research priority. Currently, many women require invasive diagnostic laparoscopy and wait over nine years for definitive diagnosis. These data support the potential of imaging with maraciclatide to address this diagnostic gap.”
Maraciclatide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.
The (abstract #1985), "Semi-quantitative Analysis of Endometriosis Subtypes Using 99mTc-Maraciclatide SPECT-CT" is available on the SNMMI website and on the Serac Healthcare website. The poster will be available here after the meeting.
For more information, please contact:
Serac Healthcare Ltd
www.serachealthcare.com
David Hail, Chief Executive
+44 (0)20 8948 0000
info@seraclifesciences.com
Francetta Carr, Communications
+44 (0)7711 010820
francettacarr@seraclifesciences.com
Notes to Editors
Serac Healthcare Ltd
Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Using these targeted technologies to underpin personalised medicine in the fields of endometriosis, inflammatory arthritis and interstitial lung disease, Serac Healthcare is focused on bringing to market effective tools to accelerate diagnosis, and to deliver earlier and more effective treatment decisions. Serac Healthcare Ltd is a wholly owned subsidiary of Serac Life Sciences Limited. www.serachealthcare.com
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit snmmi.org.
- 20/05/2026
⁹⁹ᵐTc-maraciclatide Abstracts To be Presented at SNMMI 2026
London, UK, 20 May 2026. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announces that two abstracts on 99mTc-maraciclatide will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting taking place from 30 May to 2 June in Los Angeles, USA.
Dr Druin Burch, Scientific Director at Serac Healthcare will be giving an oral presentation on “Imaging Lung Inflammation in Interstitial Lung Disease (ILD) with 99mTc-Maraciclatide – a Therapy Selection Tool?” (abstract #1910)
Session: IS04 General Clinical Specialties Scientific Session
Date: Sunday, May 31, 2026
Time: 3:30 PM - 4:45 PM
Location: Convention centre, IS room
The abstract is available here: https://www.xcdsystem.com/snmmi/program/UtDKfSi/index.cfm?pgid=3058&sid=53879&mobileappid=5387900000
Phase II preliminary data from the PRospective Evaluation of Interstitial Lung Disease progression with quantitative CT (PREDICT-ILD)’ trial have previously demonstrated that visualisation of inflammation in people with fibrotic-ILD could be feasible with 99mTc-maraciclatide.
A further abstract (#1985), Semi-quantitative Analysis of Endometriosis Subtypes Using 99mTc-Maraciclatide SPECT-CT, has been accepted for poster presentation and will be available to view in the Science Pavilion throughout the conference. Dr Burch will also be giving a short oral overview of the poster as part of the Meet the Author session:
Session: MTA01 General Clinical Specialties Meet the Author Session (#261985 MTA01-Screen 09)
Date: Sunday 31st May
Time: 1-1.45pm
Location: Science Pavilion
The abstract is available here: https://www.xcdsystem.com/snmmi/program/UtDKfSi/index.cfm?pgid=3058&sid=53877&mobileappid=5387700000
Phase 2 data from the “Detecting Endometriosis expressed inTegrins using teChneTium-99m” (DETECT) imaging study have indicated that 99mTc-maraciclatide has potential as a promising diagnostic and monitoring tool for endometriosis.
99mTc-maraciclatide has FDA Fast Track designation both for “the visualisation of inflammation in the lungs of patients with known and suspected ILD” and for “the visualisation and diagnosis of superficial peritoneal endometriosis”.
99mTc-maraciclatide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.
For more information, please contact:
Serac Healthcare Ltd
www.serachealthcare.com
David Hail, Chief Executive Officer
+44 (0)208 948 0000
info@seraclifesciences.com
Francetta Carr, Communications Director
+44 (0)7711 010820
francettacarr@seraclifesciences.com
Notes to Editors
About Serac Healthcare Ltd
Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Using these targeted technologies to underpin personalised medicine in the fields of endometriosis, inflammatory arthritis and interstitial lung disease, Serac Healthcare is focused on bringing to market effective tools to accelerate diagnosis, and to deliver earlier and more effective treatment decisions. Serac Healthcare Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.
About 99mTc-maraciclatide
99mTc-maraciclatide is a radio-labelled tracer which binds with high affinity to αvβ3 integrin, a cell-adhesion molecule which is up-regulated in vascular endothelial cells during angiogenesis, a key biological process that occurs during inflammation.
About SNMMI: www.snmmi.org/AM